LEP and metabolic dysfunction-associated steatotic liver disease: In animal models, leptin has been found to alleviate hepatic steatosis by inhibiting the de novo synthesis of hepatic lipids (DNL) in the early stages of NAFLD disease, but promoting inflammation and hepatic fibrosis in the progressive stages of NAFLD disease [77, 78].